Dyne Therapeutics, Inc.
DYN
25 insider filings · Latest: May 13, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | May 4 8:59 PM | Atlas Venture Associates XI, LP | Proposed Sale | 61 | $17.39 | $1.1K | — | View → |
| Apr 28, 2026 | Apr 30 9:22 PM | Jason P RhodesDirector | Sale | 227,337 | $18.38 | $4.2M | 1,158,923(I) | View → |
| Apr 28, 2026 | Apr 28 8:44 PM | Atlas Venture Opportunity Fund I, LP | Proposed Sale | 47,103 | $18.04 | $849.7K | — | View → |
| Apr 28, 2026 | Apr 28 8:43 PM | Atlas Venture Fund XI, LP | Proposed Sale | 119,167 | $18.04 | $2.1M | — | View → |
| Apr 28, 2026 | Apr 28 8:43 PM | Atlas Venture Opportunity Fund II, LP | Proposed Sale | 59,836 | $18.04 | $1.1M | — | View → |
| Apr 28, 2026 | Apr 28 8:42 PM | Atlas Venture Associates XI, LP | Proposed Sale | 1,171 | $18.04 | $21.1K | — | View → |
| Apr 27, 2026 | Apr 27 10:15 PM | Jason P RhodesDirector | Sale | 173,493 | $18.15 | $3.1M | 1,206,026(I) | View → |
| Apr 24, 2026 | Apr 27 10:15 PM | Jason P RhodesDirector | Sale | 137,948 | $18.48 | $2.5M | 1,241,973(I) | View → |
| Apr 23, 2026 | Apr 27 10:15 PM | Jason P RhodesDirector | Sale | 73,108 | $19.19 | $1.4M | 1,270,556(I) | View → |
| Apr 27, 2026 | Apr 27 8:49 PM | Atlas Venture Opportunity Fund II, LP | Proposed Sale | 45,709 | $18.26 | $834.6K | — | View → |
| Apr 27, 2026 | Apr 27 8:48 PM | Atlas Venture Opportunity Fund I, LP | Proposed Sale | 35,947 | $18.26 | $656.4K | — | View → |
| Apr 27, 2026 | Apr 27 8:48 PM | Atlas Venture Fund XI, LP | Proposed Sale | 90,943 | $18.26 | $1.7M | — | View → |
| Apr 27, 2026 | Apr 27 8:48 PM | Atlas Venture Associates XI, LP | Proposed Sale | 894 | $18.26 | $16.3K | — | View → |
| Apr 24, 2026 | Apr 24 8:47 PM | Atlas Venture Opportunity Fund I, LP | Proposed Sale | 28,583 | $18.90 | $540.2K | — | View → |
| Apr 24, 2026 | Apr 24 8:46 PM | Atlas Venture Opportunity Fund II, LP | Proposed Sale | 36,345 | $18.90 | $686.9K | — | View → |
| Apr 24, 2026 | Apr 24 8:46 PM | Atlas Venture Fund XI, LP | Proposed Sale | 72,310 | $18.90 | $1.4M | — | View → |
| Apr 24, 2026 | Apr 24 8:45 PM | Atlas Venture Associates XI, LP | Proposed Sale | 710 | $18.90 | $13.4K | — | View → |
| Apr 23, 2026 | Apr 23 8:46 PM | Atlas Venture Opportunity Fund I, LP | Proposed Sale | 15,148 | $19.67 | $298.0K | — | View → |
| Apr 23, 2026 | Apr 23 8:45 PM | Atlas Venture Opportunity Fund II, LP | Proposed Sale | 19,261 | $19.67 | $378.9K | — | View → |
| Apr 23, 2026 | Apr 23 8:45 PM | Atlas Venture Fund XI, LP | Proposed Sale | 38,322 | $19.67 | $753.8K | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | Feb 17 10:11 PM | John CoxDirector, CEO & President | Grant/Award | 285,000 | $16.00 | 285,000(D) | View → |
| Feb 12, 2026 | Feb 17 10:10 PM | Douglas KerrChief Medical Officer | Grant/Award | 130,000 | $16.00 | 130,000(D) | View → |
| Feb 12, 2026 | Feb 17 10:09 PM | Johanna Friedl-NadererChief Commercial Officer | Grant/Award | 90,000 | $16.00 | 90,000(D) | View → |
| Feb 12, 2026 | Feb 17 10:08 PM | Erick LuceraChief Financial Officer | Grant/Award | 105,000 | $16.00 | 105,000(D) | View → |